KORU Medical Systems, Inc. (KRMD): A Bull Case Theory
We came across a bullish thesis on KORU Medical Systems, Inc. (KRMD) on Substack by Shareholdersunite. In this article, we will summarize the bulls' thesis on KRMD. KORU Medical Systems, Inc. (KRMD)'s share was trading at $3.58 as of Feb 26th. KRMD's trailing P/E was 398.47 according to Yahoo Finance.
Ideya/Shutterstock.com
KORU Medical (KRMD) is a leader in subcutaneous drug delivery solutions, providing patient-friendly infusion systems that are transforming the market. After a period of overvaluation, a recent correction has created an attractive entry point, as KORU benefits from strong industry tailwinds, including the shift from intravenous to subcutaneous immunoglobulin (SCIg), greater adoption of prefilled syringes, international expansion, and its growing role in novel therapy development. The company's FREEDOM System, consisting of portable, maintenance-free infusion devices and consumables, has established itself as a preferred solution for treating conditions like primary immunodeficiency diseases (PIDD), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Paroxysmal Nocturnal Hemoglobinuria (PNH), providing superior patient comfort while reducing healthcare costs.
KORU's recurring revenue model, driven by its high-margin consumables business, ensures consistent growth. Its multi-channel sales and distribution approach, which includes direct supply agreements with pharmaceutical companies, specialty pharmacies, and home infusion providers, reinforces its market penetration. Additionally, strict quality controls in U.S. and Nicaraguan manufacturing facilities guarantee compliance with regulatory standards. The company is also investing in R&D to develop a next-generation infusion system, further strengthening its market position.
The domestic core business remains the backbone of KORU's growth, with revenue increasing 14% in Q2 2024 and 12% in Q3, outpacing the broader SCIg market. This momentum is driven by growing patient adoption, expanded SCIg drug labels such as XEMBIFY, and a rising CIDP market. Prefilled syringe adoption is another significant tailwind, enhancing convenience and compatibility with KORU's devices. Internationally, the company has seen strong growth, with adjusted revenue increases of 20% in Q2 and 24% in Q3, bringing year-to-date international growth to 38%. With operations now spanning 25 countries and 26 global distributors, KORU is well-positioned to capitalize on expanding SCIg adoption in new markets like Japan and Austria.
Novel Therapies is an emerging high-growth segment, with revenues surging 276% in Q3 2024 following a 50% increase in Q2. This segment, which includes feasibility studies, clinical trials, and engineering services for pharmaceutical companies developing subcutaneous biologics, represents a significant long-term growth opportunity. As more therapies transition to subcutaneous delivery, KORU's FREEDOM System stands to benefit, reinforcing its leadership in this expanding market.
Financially, KORU has delivered strong performance, with total revenue increasing 17% to $8.2M in Q3 2024, led by 12% growth in domestic core sales and 5% in international sales, which normalized to 25% after accounting for Q2 BSI stocking orders. The Novel Therapies segment contributed $600K, driven by robust product sales supporting clinical trials and non-recurring engineering (NRE) services for six pharmaceutical collaborations. Preliminary Q4 results indicate revenue growth of 23% to $8.9M, bringing FY24 growth to 18% at $33.7M.
Profitability is improving, with gross profit up 19% and margins expanding 140 basis points to 63.4%, aided by higher NRE margins and price increases. Cash flow is turning positive, with preliminary Q4 figures showing a $9.6M cash balance, reflecting $0.8M positive cash flow for the quarter and a 67% reduction in FY24 cash burn. With zero debt and access to a $10M credit facility, KORU is financially stable. FY24 guidance has been raised to $32.75M-$33.25M, though preliminary results suggest an even stronger $33.9M. Gross margins are projected at 62%-63%, while operating expenses are expected to land at $24.5M-$25M, excluding stock compensation. KORU anticipates achieving cash flow breakeven in Q4 and sustained positive cash flow in 2025.
At $3.6 per share, KORU's market cap stands at $170M, with an enterprise value of $160.5M. It is projected that FY25 revenue of $38.4M, equating to a 4.17x EV/S multiple. While a $0.07 EPS loss is expected, the company's improving fundamentals, margin expansion, and accelerating growth in novel therapies suggest further upside. Despite difficult comps in FY25, momentum is expected to strengthen in FY26, reinforcing the long-term investment case. Investors may find the current $3.5-$3.7 range an attractive entry point, as KORU's disciplined financial management and multiple growth drivers position it for sustained success.
KORU Medical Systems, Inc. (KRMD) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 15 hedge fund portfolios held KRMD at the end of the third quarter which was 6 in the previous quarter. While we acknowledge the risk and potential of KRMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than KRMD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
New law: When do fireworks sales start in Arkansas now?
ARKANSAS (KNWA/KFTA) — Thanks to a new law, Arkansas summer celebrations might be starting earlier than you think. During the 2025 legislative session, Arkansas lawmakers approved a bill expanding the allowable sales period for fireworks during the summer months. House Bill 1324, now signed into law as Act 108 by Governor Sarah Huckabee Sanders, amends the state's fireworks regulations. Previously, fireworks sales were permitted to begin on June 20. The new law starts sales a week earlier on June 13, extending the sales period for vendors and buyers. Under the updated law, fireworks sales dates in Arkansas are: Summer: June 13 through July 10 Winter: Dec. 10 through Jan. 5 $15 wage above living cost for Arkansas DINKs, but single workers need more From 10 a.m. to 10 p.m. July 1-3 From 10 a.m. to 11 p.m. July 4 No bottle rocketsFrom 8 a.m. to 11 p.m. July 1-4 No bottle noon to 10 p.m. July 2-4 No sky lanterns or bottle 11 a.m. to 11 p.m. July 2-4 No bottle noon to midnight July 3-4 No bottle 6 p.m. to midnight from July 3-5 No bottle noon to midnight on July 1-7 Decatur From noon to 11 3-5 Farmington From 10 a.m. to 10 p.m. on July 3 & July 5 From 10 a.m. to midnight on July 4 Eureka Springs No Fireworks can be discharged within city limits. Lowell From 9 a.m. to 10 p.m. July 1-6From 8 a.m. to 11 p.m. July 1-July 4From 9 a.m. to 10 p.m. June 30-July 6 From 9 a.m. to 11 p.m. July 3-4 Fort Smith No Fireworks can be discharged within city limits. Barling No Fireworks can be discharged within city limits. Sallisaw, Oklahoma From 10 a.m. to midnight July 1-4 Muldrow, Oklahoma From 8 a.m. to midnight July 3-4 Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Jeff Bezos And Lauren Sanchez's Wedding Date Confirmed As Guests Prepare To Arrive In Venice
After months of speculation, reports have emerged confirming the date of Jeff Bezos and Lauren Sanchez's Venice wedding. Previously, it was rumored that the date was between June 24 and June 29. Now, the precise date has been revealed, and it would occur on the island of San Giorgio. Jeff Bezos and Lauren Sanchez have reportedly rented out the island for the festivities, and private vessels have been secured for logistical arrangements. Ahead of Bezos and Sanchez's nuptials later this month, a source has confirmed what date the couple will exchange vows. Speaking with the Daily Mail, the insider claimed that the lovebirds picked June 27, which falls between the previously rumored timeline of June 24 to June 29. The exact location also appears to be Venice's San Giorgio, one of the most prestigious islands in the city and home to a 16th-century Benedictine church of the same name. Already, the couple is said to have rented out the island for six days, during which no visitors will be allowed. Meanwhile, off the coast of the island, Bezos's $500 million superyacht Koru will be moored all through the festivities. Although it is unclear what role the 127 m-long vessel will play during the festivities, the soon-to-be couple has secured a private tender service and other vessels to carry guests to and from Koru, as well as to cater to other logistical arrangements. Beyond the wedding date confirmation, the source also revealed that the couple has two other high-profile events planned as part of their wedding festivities. They claimed that the duo set aside June 26 for a gala at a private cloister along the iconic Lid, potentially at Chiostro della Madonna dell'Orto. The soon-to-be couple is said to have also made plans for a lavish party on June 28 at a palazzo or church. There, guests will possibly be treated to an array of pastries, as suggested by prior reports that Bezos and Sanchez enlisted the services of local bakery Rosa Salva Venetia. The bakery is renowned for making treats such as tiramisu, cream-filled flaky pastries, and fritelle, a traditional Italian fried delicacy. When the festivities are over, guests will reportedly receive handcrafted glassware made by a local artisan brand, Laguna B, as a souvenir. According to the Daily Mail, the glass pieces come in a variety of motifs and designs, featuring bright colors, stripes, and floral patterns. One large-sized cup from the collection retails for $167, although it is unclear how much the soon-to-be couple paid to have the gift item made for their guests. Alongside this glassware, guests will also receive other "opulent" gifts for attending the $7 million wedding. What these gifts are remains unclear, but fun designer purses could be among them, as Sanchez is a fan of these luxurious items. It is expected that guests will begin to arrive in Venice over the next few days for the upcoming nuptials. Bezos and Sanchez chose to keep their invitee list moderate, with 200 being the number of guests expected. The list comprises friends, family, and business partners of the couple, including names such as Kim Kardashian, Kris Jenner, Katy Perry, Orlando Bloom, and even members of the Trump family, who are already rumored to be on the list. These guests have reportedly booked accommodations in most of the top hotels in the city. This includes The Aman Venice, where rooms cost over $2,700 per night, and Hotel Cipriani, which, though slightly less expensive, still comes in at a steep $2,000 per night. As for Bezos and Sanchez, they are said to have reserved the Grand Canal Suite at the five-star Aman Venice at a whopping $11,600 per night. "[It is] the biggest they have, and it's the talk of the hotel," a source told The Sun. "The room is spectacular and even has access to a rooftop terrace overlooking the city. Bezos proposed to Sánchez in May 2023, years after their public debut as a couple in January 2019. Before their relationship, Bezos was married to MacKenzie Scott for 25 years, while Sánchez was with her former husband, Patrick Whitesell. Though the pair is often seen on Bezos's yacht or enjoying extravagant getaways, Sánchez told People Magazine in August that their happiest moments are usually the simplest. "My favorite time is when the house is calm and quiet, and Jeff and I are deciding what show we're going to binge that night," Sánchez said.
Business Upturn
8 hours ago
- Business Upturn
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc. , No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Tempus AI class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI. The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (ii) the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus AI; (iii) Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (iv) AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable 'pass-through payment' via a joint agreement between it, Tempus AI, and Pathos AI, Inc.; and (v) the above issues revealed weakness in core operations and revenue prospects. The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research report on Tempus AI that raised numerous red flags over Tempus AI's management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff in the Tempus AI class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Tempus AI class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Tempus AI class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
